A
Alcista
Alcista · 25%SLS
$1.80
Precio del escenario
$11.340
-0.516 (-4.55%)Al cierre
Loading chart…
- Máximo
- 11.920
- Apertura
- 11.500
- Precio medio ponderado por volumen
- 11.47
- Volumen
- 4.66M
- Capitalización
- 65.84M
- Mínimo
- 11.150
- Importe
- 53.40M
- EV/EBITDA, TTM
- 0.00
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Análisis de IA of Sellas Life Sciences Group Inc (SLS)
ComprarSellas Life Sciences Group Inc is a good buy right now due to its current price of $11.65, which is significantly below the analyst price target of $30, suggesting a potential upside of over 157%. Additionally, the stock has shown a remarkable year-to-date change of +167.82%, indicating strong investor interest and momentum. However, the main risk is the ongoing negative net income, which reached -9,605,000 USD in Q2 2026, highlighting the company's financial challenges.
Métricas de valoración
El PER previsto actual de Sellas Life Sciences Group Inc (SLS) es 0.00, frente a su media de 5 años de -2.91.
Escenarios de precio de Alphio AI para SLS
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con SLS en cartera
Cronología de eventos
Noticias
8.510-14stocktwitsInvestors Increase Stakes in Sellas and ImmunityBio
7.010-14stocktwitsBank of America Fined $1.2 Billion for Compliance Failures
9.510-12stocktwitsThird Quarter Earnings Season Officially Begins
8.510-12stocktwitsSellas Life Sciences Shares Rise 3% Amid ASH Meeting Speculation
2.010-08stocktwitsVenetoclax Treatment Shows Promise in AML Study
Preguntas frecuentes sobre SLS, respondidas por Alphio AI
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Sellas Life Sciences Group Inc is a good buy right now due to its current price of $11.65, which is significantly below the analyst price target of $30, suggesting a potential upside of over 157%. Additionally, the stock has shown a remarkable year-to-date change of +167.82%, indicating strong investor interest and momentum. However, the main risk is the ongoing negative net income, which reached -9,605,000 USD in Q2 2026, highlighting the company's financial challenges.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.